Table 14.2.2.1.2 Clinical benefit rate - EEP set (N = 47)

		Cohort I Murlentamab N = 13	Cohort II Murlentamab + Trifluridine/tipiracil		
			Cohort II N = 13	Cohort II expansion N = 21	Total N = 34
Clinical benefit rate at 8 weeks	N	13	13	21	34
	Missing values	0	0	0	0
	No	13 (100.0%) [100.00 ; 100.00]	11 (84.6%) [65.00 ; 100.00]	21 (100.0%) [100.00 ; 100.00]	32 (94.1%) [86.21 ; 100.00]
	Yes	0 (0.0%) [- ; -]	2 (15.4%) [0.00 ; 35.00]	0 (0.0%) [- ; -]	2 (5.9%) [0.00 ; 13.79]
Clinical benefit rate at 16 weeks	N	13	13	21	34
	Missing values	0	0	0	0
	No	13 (100.0%) [100.00 ; 100.00]	11 (84.6%) [65.00 ; 100.00]	21 (100.0%) [100.00 ; 100.00]	32 (94.1%) [86.21 ; 100.00]
	Yes	0 (0.0%) [- ; -]	2 (15.4%) [0.00 ; 35.00]	0 (0.0%) [- ; -]	2 (5.9%) [0.00 ; 13.79]

Clinial benfit rate: proportion of patients who are non-progressors (radiologically and clinically, including responders and stabilized patients, using RECIST 1.1 and iRECIST criteria) from the first administration of murlentamab (cohort I) or murlentamab + trifluridine/tipiracil (Cohort II) at 8 (+/- 10 days) and 16 (+/- 15 days) weeks

Table 14.2.2.1.16 Clinical benefit rate - mITT set (N = 65)

		Cohort I Murlentamab N = 21	Cohort II Murlentamab + Trifluridine/tipiracil		
			Cohort II N = 18	Cohort II expansion N = 26	Total N = 44
Clinical benefit rate at 8 weeks	N	21	18	26	44
	Missing values	0	0	0	0
	No	21 (100.0%) [100.00 ; 100.00]	16 (88.9%) [74.37 ; 100.00]	26 (100.0%) [100.00 ; 100.00]	42 (95.5%) [89.30 ; 100.00]
	Yes	0 (0.0%) [- ; -]	2 (11.1%) [0.00 ; 25.63]	0 (0.0%) [- ; -]	2 (4.5%) [0.00 ; 10.70]
Clinical benefit rate at 16 weeks	N	21	18	26	44
	Missing values	0	0	0	0
	No	21 (100.0%) [100.00 ; 100.00]	16 (88.9%) [74.37 ; 100.00]	26 (100.0%) [100.00 ; 100.00]	42 (95.5%) [89.30 ; 100.00]
	Yes	0 (0.0%) [- ; -]	2 (11.1%) [0.00 ; 25.63]	0 (0.0%) [- ; -]	2 (4.5%) [0.00 ; 10.70]

Clinial benfit rate: proportion of patients who are non-progressors (radiologically and clinically, including responders and stabilized patients, using RECIST 1.1 and iRECIST criteria) from the first administration of murlentamab (cohort I) or murlentamab + trifluridine/tipiracil (Cohort II) at 8 (+/- 10 days) and 16 (+/- 15 days) weeks

Table 14.2.2.2.2 Clinical benefit rate - EEP set (N = 47)

		Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
		AMHRII membrane expression < 20% N = 6	**AMHRII membrane expression ≥ 20% N = 3**	**AMHRII membrane expression < 20% N = 17**	**AMHRII membrane expression ≥ 20% N = 13**
Clinical benefit rate at 8 weeks	N	6	3	17	13
	Missing values	0	0	0	0
	No	6 (100.0%) [100.00 ; 100.00]	3 (100.0%) [100.00 ; 100.00]	17 (100.0%) [100.00 ; 100.00]	11 (84.6%) [65.00 ; 100.00]
	Yes	0 (0.0%) [- ; -]	0 (0.0%) [- ; -]	0 (0.0%) [- ; -]	2 (15.4%) [0.00 ; 35.00]
Clinical benefit rate at 16 weeks	N	6	3	17	13
	Missing values	0	0	0	0
	No	6 (100.0%) [100.00 ; 100.00]	3 (100.0%) [100.00 ; 100.00]	17 (100.0%) [100.00 ; 100.00]	11 (84.6%) [65.00 ; 100.00]
	Yes	0 (0.0%) [- ; -]	0 (0.0%) [- ; -]	0 (0.0%) [- ; -]	2 (15.4%) [0.00 ; 35.00]

Clinial benfit rate: proportion of patients who are non-progressors (radiologically and clinically, including responders and stabilized patients, using RECIST 1.1 and iRECIST criteria) from the first administration of murlentamab (cohort I) or murlentamab + trifluridine/tipiracil (Cohort II) at 8 (+/- 10 days) and 16 (+/- 15 days) weeks

Table 14.2.2.2.16 Clinical benefit rate - mITT set (N = 65)

		Cohort I Murlentamab		Cohort II Murlentamab + Trifluridine/tipiracil	
		AMHRII membrane expression < 20% N = 12	**AMHRII membrane expression ≥ 20% N = 4**	**AMHRII membrane expression < 20% N = 24**	**AMHRII membrane expression ≥ 20% N = 16**
Clinical benefit rate at 8 weeks	N	12	4	24	16
	Missing values	0	0	0	0
	No	12 (100.0%) [100.00 ; 100.00]	4 (100.0%) [100.00 ; 100.00]	24 (100.0%) [100.00 ; 100.00]	14 (87.5%) [71.29 ; 100.00]
	Yes	0 (0.0%) [- ; -]	0 (0.0%) [- ; -]	0 (0.0%) [- ; -]	2 (12.5%) [0.00 ; 28.71]
Clinical benefit rate at 16 weeks	N	12	4	24	16
	Missing values	0	0	0	0
	No	12 (100.0%) [100.00 ; 100.00]	4 (100.0%) [100.00 ; 100.00]	24 (100.0%) [100.00 ; 100.00]	14 (87.5%) [71.29 ; 100.00]
	Yes	0 (0.0%) [- ; -]	0 (0.0%) [- ; -]	0 (0.0%) [- ; -]	2 (12.5%) [0.00 ; 28.71]

Clinial benfit rate: proportion of patients who are non-progressors (radiologically and clinically, including responders and stabilized patients, using RECIST 1.1 and iRECIST criteria) from the first administration of murlentamab (cohort I) or murlentamab + trifluridine/tipiracil (Cohort II) at 8 (+/- 10 days) and 16 (+/- 15 days) weeks